Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Miyamura, Tatsuo ^a   Kanda, Tatsuo ^a   Nakamoto, Shingo ^a   Wu, Shuang ^a   Fujiwara, Keiichi ^a   Imazeki, Fumio ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; STAT1 PROTEIN; VIRUS RNA; ALPHA INTERFERON; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; STAT1 PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; ASIAN; CELL NUCLEUS; DRUG EFFECT; GENETICS; JAPAN; LIVER; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTEIN TRANSPORT; SINGLE NUCLEOTIDE POLYMORPHISM; VIROLOGY;

ASIAN CONTINENTAL ANCESTRY GROUP; CELL NUCLEUS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; INTERLEUKINS; JAPAN; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TRANSPORT; RECOMBINANT PROTEINS; RIBAVIRIN; STAT1 TRANSCRIPTION FACTOR; TREATMENT OUTCOME;

EID: 83155167582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028617     Document Type: Article

References (32)

1. Lavanchy D, (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17: 107-115.
2. Bacon BR, Khalid O, (2011) New therapies for hepatitis C virus infection. Mo Med 108: 255-259.
3. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, et al. (2011) Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 53: 1100-1108.
4. Di Bisceglie AM, Hoofnagle JH, (2002) Optimal therapy of hepatitis C. Hepatology 36: S121-S127.
5. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, et al. (2008) Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47: 1837-1845.
6. Kanda T, Imazeki F, Yokosuka O, (2010) New antiviral therapies for chronic hepatitis C. Hepatology Int 4: 548-561.
7. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
8. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
9. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
10. Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, et al. (2011) Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol 46: 955-961.
11. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, et al. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81: 7749-7758.
12. Mowen K, David M, (1998) Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1. J Biol Chem 273: 30073-30076.
13. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, et al. (2005) The novel lambda-interferons IL-28A and IL-29 mediate proinflammatory, antiproliferative, and antiviral signals in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 289: G960-G968.
14. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501-4509.
15. Basu A, Meyer K, Ray RB, Ray R, (2001) Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 288: 379-390.
16. Basu A, Meyer K, Lai KK, Saito K, Di Bisceglie AM, et al. (2006) Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 349: 347-358.
17. Chen L, Borozan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437-1444.
18. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 105: 7034-7039.
19. Honda M, Sakai A, Yamashita T, Makamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509.
20. Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, et al. (2011) Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 6: e17232.
21. Tsukiyama-Kohara K, Yamaguchi K, Maki N, Ohta Y, Miki K, et al. (1993) Antigenicities of group I and II hepatitis C virus polypeptides-molecular basis of diagnosis. Virology 192: 430-437.
22. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, et al. (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 74: 2391-2399.
23. Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, et al. (2011) Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test. J Viral Hepat 18: e292-e297.
24. Rappaport AM, (1976) The microcirculately acinar concept of normal and pathological hepatic structure. Beitr Pathol 157: 215-243.
25. Volpes R, van den Oord JJ, De Vos R, Depla E, De Ley M, et al. (1991) Expression of interferon-gamma receptor in normal and pathological human liver tissue. J Hepatol 12: 195-202.
26. Honda M, Nakamura M, Tateno M, Sakai A, Shimakami T, et al. (2010) Differential interferon signaling in liver lobule and portal area cells under treatment for chronic hepatitis C. J Hepatol 53: 817-826.
27. Ma D, Jiang D, Qing M, Weidner JM, Qu X, et al. (2009) Antiviral effect of interferon lambda against West Nile virus. Antiviral Res 83: 53-60.
28. Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK, (2007) Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat 14: 721-729.
29. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896.
30. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, et al. (2011) IL28B variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 54: 1094-1101.
31. Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, et al. (2011) Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 83: 1597-1607.
32. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patient with hepatitis C. Gastroenterology 140: 1021-1031.